Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vapreotide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 known ✓ | P30874 | 16/20 | 0.81 |
| ▸ | SSTR5 known ✓ | P35346 | 15/20 | 0.81 |
| ▸ | SSTR3 known ✓ | P32745 | 8/20 | 0.78 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.78 |
| ▸ | SSTR4 | P31391 | 7/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vapreotide SCHEMBL4827 | 1.00 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL29405608 | 1.00 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL4826 | 1.00 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL31632623 | 1.00 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL30163296 | 1.00 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL29580907 | 0.99 | SSTR2 (0.80) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL294911 | 0.99 | SSTR2 (0.80) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL29384009 | 0.99 | SSTR2 (0.80) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL5200070 | 0.97 | SSTR2 (0.78) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| SCHEMBL23482743 | 0.97 | SSTR5 (0.78) | SSTR2SSTR5SSTR3SSTR1SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160045463-A1 | USE OF METALLOPROTEASE INHIBITORS IN THE TREATMENT OF POLYCYSTIC LIVER DISEASES | UNIVERSIDAD DE SALAMANCA (ES) | 2016-02-18 | — | — | US | disclosed |
| EP-2926808-A1 | USE OF METALLOPROTEASE INHIBITORS FOR THE TREATMENT OF POLYCYSTIC LIVER DISEASES | Administración General De La Communidad Autónoma De Euskadi (ES) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014083229-A1 | USE OF METALLOPROTEASE INHIBITORS FOR THE TREATMENT OF POLYCYSTIC LIVER DISEASES | ADMINISTRACIÓN GENERAL DE LA COMUNIDAD AUTÓNOMA DE EUSKADI (ES) | 2014-06-05 | — | — | WO | disclosed |
| US-6852688-B2 | Compositions for treating diabetic retinopathy and methods of using same | UNIVERSITY OF FLORIDA (US) | 2005-02-08 | — | — | US | disclosed |
| US-20020045569-A1 | Compositions for treating diabetic retinopathy and methods of using same | FLORIDA, UNIVERSITY OF | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045463-A1 | USE OF METALLOPROTEASE INHIBITORS IN THE TREATMENT OF POLYCYSTIC LIVER DISEASES | PKD1, MMP3, PKD2 | SSTR2 1958/4885SSTR5 1131/4885SSTR3 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.